Combination of N ‐acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non‐alcoholic steatohepatitis
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aim: There is no proven medical therapy for the treatment of non‐alcoholic steatohepatitis (NASH). Oxidative stress and insulin resistance are the mechanisms that seem to be mostly involved in its pathogenesis. The aim of our study was to evaluate the efficacy of N ‐acetylcysteine (NAC) in combination with metformin (MTF) in improving the aminotransferases and histological parameters (steatosis, inflammation, hepatocellular ballooning, and fibrosis) after 12 months of treatment. Methods: Twenty consecutive patients (mean age 53 ± 2 years [36–68] and body mass index [BMI] 29 [25–35]) with biopsy‐proven NASH were enrolled in the study. NAC (1.2 g/day) and MTF (850–1000 mg/day) were given orally for 12 months. All patients underwent evaluation of serum aminotransferases, fasting lipid profile and serum glucose, anthropometric parameters, and nutritional status at 0 and 12 months. A low calorie diet was prescribed for all patients. Results: Serum alanine aminotransferase, high‐density lipoprotein, insulin, and glucose concentrations and thehomeostasis model assessment–insulin resistance (HOMA‐IR) index were reduced significantly at the end of study ( P < 0.05). The BMI declined, but without statistical significance. Aspartate aminotransferase, gamma‐glutamyl transferase, alkaline phosphatase, cholesterol, and triglycerides levels were not altered with the treatment. Liver steatosis and fibrosis decreased ( P < 0.05), but no improvement was noted in lobular inflammation or hepatocellular ballooning. The NASH activity score was significantly improved after treatment. Conclusion: Based on the biochemical and histological evidence in this pilot study, NAC in combination with MTF appears to ameliorate several aspects of NASH, including fibrosis. Further studies of this form of combination therapy are warranted to assess its potential efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Grundy, S. M., Hansen, B., Smith, S. C., Cleeman, J. I., Kahn, R. A., & Participants, F. C. (2004) · Circulation · doi:10.1161/01.cir.0000112379.88385.67 · Cited by 864
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology · doi:10.1002/hep.20092 · Cited by 727
Metformin in non-alcoholic steatohepatitis.
Marchesini, G., Bianchi, G., Tomassetti, S., Zoli, M., & Melchionda, N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06042-1 · Cited by 682
(2004) · Seminars in Liver Disease · doi:10.1055/s-2004-823098 · Cited by 481
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial
Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., & Perrillo, R. P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02025.x · Cited by 369
Hepatic Steatosis: A Mediator of the Metabolic Syndrome. Lessons From Animal Models
den Boer, M., Voshol, P. J., Kuipers, F., Havekes, L. M., & Romijn, J. A. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000116217.57583.6e · Cited by 260
Nonalcoholic Fatty Liver Disease: Pathogenesis and the Role of Antioxidants
Mehta, K., Van Thiel, D. H., Shah, N., & Mobarhan, S. (2002) · Nutrition Reviews · doi:10.1301/002966402320387224 · Cited by 250
Cited by
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
Hepatic inflammation and progressive liver fibrosis in chronic liver disease
Czaja, A. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2515 · Cited by 342
Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease
Gentric, G., Maillet, V., Paradis, V., Couton, D., L’Hermitte, A., Panasyuk, G., Fromenty, B., Celton-Morizur, S., & Desdouets, C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73957 · Cited by 240
Cufí, S., Vazquez-Martin, A., Oliveras-Ferraros, C., Martin-Castillo, B., Joven, J., & Menendez, J. A. (2010) · Cell Cycle · doi:10.4161/cc.9.22.14048 · Cited by 216
Metadata
- Authors
- De Oliveira, C. P. M. S., Stefano, J. T., De Siqueira, E. R. F., Silva, L. S., De Campos Mazo, D. F., Lima, V. M. R., Furuya, C. K., Mello, E. S., Souza, F. G., Rabello, F., Santos, T. E., Nogueira, M. A., Caldwell, S. H., Alves, V. A. F., & Carrilho, F. J.
- Venue
- Hepatology Research
- Publisher
- Wiley
- Published
- 2007-08-09
- Volume
- 38
- Issue
- 2
- Pages
- 159-165
- ISSN
- 1386-6346 (ISSN-L)
- 1872-034X
- OpenAlex
- W1994378142
- Cited by
- 109
- References
- 9
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination of N ‐acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non‐alcoholic steatohepatitis. https://app.cochat.ai/papers/10.1111/j.1872-034x.2007.00215.x
- The paper
- De Oliveira, C. P. M. S., Stefano, J. T., De Siqueira, E. R. F., Silva, L. S., De Campos Mazo, D. F., Lima, V. M. R., Furuya, C. K., Mello, E. S., Souza, F. G., Rabello, F., Santos, T. E., Nogueira, M. A., Caldwell, S. H., Alves, V. A. F., & Carrilho, F. J. (2008). Combination of N ‐acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non‐alcoholic steatohepatitis. Hepatology Research. https://doi.org/10.1111/j.1872-034x.2007.00215.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.